Legal Representation
Attorney
Eva Gullick Frongello
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 28, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 28, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| May 8, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| May 8, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| May 8, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| May 8, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| May 8, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Jan 24, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 29, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 29, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 9, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 24, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 12, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 12, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 12, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 12, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 12, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 12, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 10, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 4, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Aug 13, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer
Class 042
pharmaceutical research and development services; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
Class 044
Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer
Classification
International Classes
005
042
044